Background: Migraine is a highly prevalent neurological disorder. Conventional therapies may be limited by side effects and suboptimal efficacy. Cannabidiol (CBD) has emerged as a potential alternative therapy with a more favorable safety profile. Methods: In this 12-week prospective observational cohort study, we evaluated the safety, feasibility, and preliminary efficacy of two full-spectrum CBD-rich oils—industrial and artisanal—for chronic migraine in 40 individuals that began self-medicating with either oil (N = 20 per group), provided through an existing initiative by an industrial company and a patient association. The oil was titrated individually to reach a target dose of 100 mg/day of CBD. Assessments were conducted using the Migraine Disability Assessment Questionnaire (MIDAS), Headache Impact Test (HIT-6), Mini Sleep Questionnaire (MSQ), and the World Health Organization Quality of Life—5-item version (WHOQOL-5). Results: Both formulations led to improvements in migraine-related disability, headache impact, quality of life, quality of sleep, and subjective well-being. Adverse events occurred at similar rates across groups. Conclusions: In sum, full-spectrum CBD-rich oil—both industrial and artisanal—appears effective in reducing migraine burden in individuals with chronic migraine, while maintaining an acceptable side effects profile. These findings support the need for randomized controlled trials to determine the lowest and most effective regimens, and cannabinoid compositions.
Bitencourt et al. (2026) studied this question.